Effect of Jianpi Bushen formula on aromatase-inhibitor-associated bone loss after menopause
نویسندگان
چکیده
منابع مشابه
Aromatase inhibitor-associated bone loss.
273 A 49-year-old postmenopausal Caucasian woman named M.A. was diagnosed with estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, HER2-negative breast cancer. Anthracycline and taxane-based adjuvant chemotherapy and radiation therapy were followed by adjuvant therapy with an aromatase inhibitor (AI). Before M.A. started adjuvant AI therapy, she was evaluated for any additiona...
متن کاملBone loss and bone size after menopause.
BACKGROUND Bone loss increases after menopause. However, bone strength also depends on structural characteristics such as bone size. Whether bone size increases as a result of periosteal apposition and whether a strength index accounting for both bone density and bone size might predict the risk of fracture better than bone density alone are unclear. METHODS Bone mass and the skeletal structu...
متن کاملBone Loss and Bone Size after Menopause
From the Departments of Orthopedics (H.G.A., O.J., M.K.K.) and Obstetrics and Gynecology (G.R.), Malmö University Hospital, Malmö, Sweden; and the Department of Orthopedic Surgery and the Biomechanics and Biomaterials Research Center, Indiana University, Indianapolis (C.H.T.). Address reprint requests to Dr. Ahlborg at the Department of Orthopedics, Malmö University Hospital, SE-205 02 Malmö, S...
متن کاملPreventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
BACKGROUND This study aims to compare the efficacy and safety between zoledronic acid combined with calcium and calcium alone to prevent aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole. METHODS One hundred twenty patients were randomly divided into two groups, A and B. Patients in group A (n=60) received modified radical mastecto...
متن کاملPractical guidance for the management of aromatase inhibitor-associated bone loss.
BACKGROUND Recent studies indicate that women with breast cancer are at increased risk of fracture compared with their age-matched peers. Current treatment guidelines are inadequate for averting fractures in osteopenic women, especially those receiving aromatase inhibitor (AI) therapy. Therefore, we sought to identify clinically relevant risk factors for fracture that can be used to assess over...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Traditional Chinese Medicine
سال: 2018
ISSN: 0254-6272
DOI: 10.1016/s0254-6272(18)30987-7